Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial(HERO -aCKD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 429 participants.

Also called NCT07027774

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 429 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07027774
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07027774. Randomized; no masking; primary purpose treatment. Start 2025-07-10 (anticipated); primary completion 2027-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial(HERO -aCKD)
Condition
Chronic Kidney Disease Stage 4
Intervention (Drug)
Henagliflozin 5 mg Group
Intervention (Drug)
Henagliflozin 10 mg Group
Intervention (Drug)
Conventional therapy group
Lead sponsor
First Affiliated Hospital of Wannan Medical College (class: other)
Collaborator
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07027774
Content hash
fc224c9472fe72d7712e49761ba2025fb492a7d2a8f914157d04642277f5c2db